Klaus Edvardsen (Former)
1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents
(
- Contribution to journal › Article
- 2006
-
Mark
Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents
(
- Contribution to journal › Article
- 2004
-
Mark
Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis.
(
- Contribution to journal › Article
-
Mark
LEPREL1, a novel ER and Golgi resident member of the Leprecan family.
(
- Contribution to journal › Article
-
Mark
Identification and characterization of a human smad3 splicing variant lacking part of the linker region.
(
- Contribution to journal › Article
-
Mark
Neural progenitor cell lines inhibit rat tumor growth in vivo.
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics and splenic accumulation of N-acetylamino-3-chloro-N-(2-diethylamino-ethyl) benzamide after a single administration to rats.
(
- Contribution to journal › Article
-
Mark
Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism
(
- Contribution to journal › Article
- 2003
-
Mark
Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
(
- Contribution to journal › Article
-
Mark
Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4
(
- Contribution to journal › Article